B+
Bull case
25%
Probability
Target price
$31.00
Analysis reference price unavailable
Analysis 2026-10-10 · RankAlpha Sentiment Codex
MD
Pediatrix Medical GroupBNYSE / Health Care Equipment & Services
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$27.00
Analysis reference price unavailable
Analysis 2026-10-10 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$21.00
Analysis reference price unavailable
Analysis 2026-10-10 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-10-10
Recent news sentiment (30D)
-26.0
Negative
Company
-
Unavailable
Macro
-26.0
Negative
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+49.8
Score
AI commentary
The packet provides limited recent coverage beyond the August results. No verified post-release price reaction, analyst revisions, options data or sufficiently covered social signal is available. Zeroes in the sentiment fields mean unavailable, not neutral. The September article is secondary commentary, not a company release. The positive deterministic prior is tempered by weak forward visibility and loose peers.
RankAlpha Sentiment Codex - 2026-10-10
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2027-02-28eventTest of reaffirmed 2026 EBITDA outlookMedium impact
Pediatrix reaffirmed full-year adjusted EBITDA guidance of $280 million–$300 million after reporting $134.6 million for the first half. Reaching the range requires approximately $145.4 million–$165.4 million in the second half; that is a calculation, not additional company guidance. The date is an indicative monitoring horizon, not an announced reporting date. [#8-K-2026-08-04] [#SEC-8K-2026-08-04] SEC earnings exhibit
2027-02-28eventReimbursement gains versus transition costsMedium impact
Second-quarter same-unit reimbursement factors increased 4.0%, aided by collections, payor mix and acuity. Higher practice costs weighed on same-unit results, while revenue-cycle-transition-related restructuring expense rose to $8.5 million from $3.8 million. The operating test is whether reimbursement gains persist without continued cost pressure; the date is indicative. [#SEC-8K-2026-08-04]
2027-03-31catalystPatient-volume stabilizationHigh impact
Second-quarter same-unit revenue attributable to patient volume fell 2.1%; hospital-based services fell 2.8% and NICU days fell 3.2%. Stabilization would strengthen the durability of reimbursement-led growth, but a recovery has not been established. The date is a monitoring horizon. [#SEC-8K-2026-08-04]
Recommendation
N/A
No formal recommendation provided.
As of 2026-10-10 • Updated nightlySource: Internal modelMethodology